KEY POINTS: 1. Coagulation testing is used diagnostically, prognostically and to assess bleeding and thrombotic risk. 2. Hypocoagulable, hypercoagulable and hyperfibrinolytic states exist in hepatobiliary disease. 3. Minimum bleeding risk assessment should include platelet count, PT, aPTT, hematocrit and fibrinogen. 4. There is growing evidence that thromboelastography may have value in predicting bleeding and thrombotic tendencies. 5. Evaluation of bleeding and thrombotic risk should include an individualized assessment of risk factors in each patient 6. Treatment is aimed at perceived bleeding and thrombotic risks and not simply at results of individual coagulation tests.
Upon completion, participants will be able to distinguish the diagnostic and prognostic significance of abnormal coagulation parameters in hepatobiliary disease in dogs and cats.
Upon completion, participants will be able to utilize serum-based tests and thromboelastography measurement to define hypocoagulable and hypercoagulable states in dogs and cats with hepatobiliary disease.
Upon completion, participants will be able to implement therapeutic interventions based on observed coagulation testing abnormalities in dogs and cats.